Johannes Gutenberg-Universität Mainz
- 6131/39-0
Lewin, D.; Szymanski, M. K.; Meyer, A. L. et al.
Transition from temporary microaxial left ventricular assist devices to durable mechanical circulatory support systemsEUROPEAN HEART JOURNAL. Bd. 44. 2023
Mirzac, Daniela; Kreis, Svenja L.; Luhmann, Heiko J. et al.
Translating Pathological Brain Activity Primers in Parkinson's Disease ResearchRESEARCH. Bd. 6. 2023
Iding, A. F. J.; Kremers, B. M. M.; Nagy, M. et al.
Translational insights into mechanisms underlying residual venous obstruction and the role of factor XI, P-selectin and GPVI in recurrent venous thromboembolismTHROMBOSIS RESEARCH. Bd. 221. 2023 S. 58-64
Frank, Mark; Braun, Jörg; Haelke, Laura et al.
Traumatic Cardiac Arrest in Polytrauma–There are Survivors: A 10-Year Analysis from a German Helicopter BasePreshospital and Disaster Medicine. Bd. 38. 2023 S. 45
Dietz-Fricke, Christopher; Tacke, Frank; Zollner, Caroline et al.
Treating hepatitis D with bulevirtide-Real-world experience from 114 patientsJHEP REPORTS. Bd. 5. H. 4. 2023
Klar, Maximilian; Plett, Helmut; Harter, Philipp et al.
Treatment and survival of patients with malignant ovarian sex cord-stromal cell tumours: An analysis of the Arbeitsgemeinschaft fu''r Gynakologische Onkologie (AGO) study group CORSETT databaseJOURNAL OF SURGICAL ONCOLOGY. Bd. 128. H. 1. 2023 S. 111-118
Haist, Maximilian; Stege, Henner; Rogall, Friederike et al.
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREGJOURNAL FOR IMMUNOTHERAPY OF CANCER. Bd. 11. H. 9. 2023
Castera, Laurent; Fournier-Poizat, Celine; Foucquier, Julie et al.
Treatment monitoring with the Agile 3+score in patients with non-alcoholic steatohepatitis: analysis of data from a randomised placebo-controlled trial of semaglutideJOURNAL OF HEPATOLOGY. Bd. 78. 2023 S. S817-S818
Decker, T.; Brucker, C.; Engel, A. et al.
Treatment of elderly patients (pts; > 75 years) with 1st line ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL) or endocrine monotherapy (ET) in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))ONCOLOGY RESEARCH AND TREATMENT. Bd. 46. 2023 S. 168-169
Decker, T.; Brucker, C.; Fasching, P. et al.
Treatment of elderly patients (pts; > 75 years) with 1st-line ribociclib (RIB) plus endocrine therapy (ET) or endocrine monotherapy in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))ANNALS OF ONCOLOGY. Bd. 34. 2023 S. S354-S355